Cargando…
Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615872/ https://www.ncbi.nlm.nih.gov/pubmed/31354965 http://dx.doi.org/10.1136/esmoopen-2019-000537 |
| _version_ | 1783433416896675840 |
|---|---|
| author | Fernandes, Gustavo dos Santos Pereira, Allan |
| author_facet | Fernandes, Gustavo dos Santos Pereira, Allan |
| author_sort | Fernandes, Gustavo dos Santos |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6615872 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-66158722019-07-28 Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? Fernandes, Gustavo dos Santos Pereira, Allan ESMO Open Correspondence BMJ Publishing Group 2019-07-08 /pmc/articles/PMC6615872/ /pubmed/31354965 http://dx.doi.org/10.1136/esmoopen-2019-000537 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Correspondence Fernandes, Gustavo dos Santos Pereira, Allan Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? |
| title | Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? |
| title_full | Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? |
| title_fullStr | Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? |
| title_full_unstemmed | Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? |
| title_short | Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? |
| title_sort | development of new therapies for metastatic pancreatic cancer: are they better than folfirinox? |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615872/ https://www.ncbi.nlm.nih.gov/pubmed/31354965 http://dx.doi.org/10.1136/esmoopen-2019-000537 |
| work_keys_str_mv | AT fernandesgustavodossantos developmentofnewtherapiesformetastaticpancreaticcanceraretheybetterthanfolfirinox AT pereiraallan developmentofnewtherapiesformetastaticpancreaticcanceraretheybetterthanfolfirinox |